In Chicago on August 29, 2025, the Alzheimer's Association expressed approval for the U.S. Food and Drug Administration's recent decision to greenlight weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early-stage Alzheimer's disease. This move allows for the administration of Leqembi IQLIK on a regular basis, providing a significant advancement in treatment options for patients.